BCA
NVCR icon

Berman Capital Advisors’s NovoCure NVCR Stock Holding History

Berman Capital Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$11K Sell
95
-216
-69% -$32.7K ﹤0.01% 1156
2021
Q2 		$68K Buy
311
+249
+402% +$48.4K 0.01% 481
2021
Q1 		$8K Buy
+62
New +$9.81K ﹤0.01% 1111

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Berman Capital Advisors's NVCR Position: Q3 2021 in Review

Berman Capital Advisors reduced its NovoCure (NVCR) stake by 69% in Q3 2021, selling an estimated $32.7K and leaving 95 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #1156.

Berman Capital Advisors first reported a position in NVCR in Q1 2021 and has held it in 3 quarters since. The position peaked at $68K in Q2 2021. 318 funds tracked by Wall St. Rank hold NVCR as of Q3 2021.

  • Berman Capital Advisors held 95 shares of NovoCure worth $11K as of Q3 2021.
  • Berman Capital Advisors sold 216 NovoCure shares in Q3 2021, an estimated $32.7K.
  • NovoCure made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1156 holding.
  • Berman Capital Advisors first reported a position in NovoCure in Q1 2021 and has held it in 3 quarters since.
  • Berman Capital Advisors's NovoCure position peaked at $68K in Q2 2021.
  • 318 funds tracked by Wall St. Rank held NovoCure as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.